Federal Register of Legislation - Australian Government

Primary content

PB 34 of 2011 Arrangements as made
This instrument amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010) to add two new pharmaceutical benefits and make an minor administrative change.
Administered by: Health
Registered 27 Apr 2011
Tabling HistoryDate
Tabled HR10-May-2011
Tabled Senate10-May-2011
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

PB 34 of 2011

National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No. 4)

 

National Health Act 1953

___________________________________________________________________________

 

 

I, FELICITY MCNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.

Dated   20 April 2011

 

 

 

 

 

 

 

 

 

 

 

FELICITY MCNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

 

___________________________________________________________________________

 

 

 

 


1              Name of Instrument

 

(1)                This Instrument is the National Health (Highly                    

             specialised drugs program for hospitals) Special Arrangement

            Amendment Instrument 2011 (No.4).

 

(2)                This Instrument may also be cited as PB 34 of 2011.

 

2             Commencement

                             This Instrument commences on 1 May 2011.

3              Amendments to PB 116 of 2010

                Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010)

.

 

 


Schedule 1                   Amendments

[1]           Schedule 1, after entry for Lenograstim in the form Powder for injection 33,600,000 I.U. (263 micrograms)

insert in the columns in the order indicated:

Levodopa with Carbidopa

Intestinal gel 20 mg-5 mg per mL ,100 mL

Intra-intestinal

Duodopa

AB

EMP

C3704 C3705

 

56

5

D

 

[2]           Schedule 1, entry for Tocilizumab in the form Concentrate for injection 400 mg in 20 mL

            substitute:

 

Concentrate for injection 400 mg in 20 mL

Injection

Actemra

RO

EMP

C3480 C3559 C3560 C3561

 

See Note 1

See Note 2

D

 

[3]           Schedule 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride)

insert in the columns in the order indicated, in alphabetical order by brand:

 

 

 

Zelitrex

RE

EMP

C1494 C3419

 

500

2

D

 

 

[4]         Schedule 2

              after:

PF

Pfizer Australia Pty Ltd

50 008 422 348

 

             insert:

RE

GlaxoSmithKline Australia Pty Ltd

47 100 162 481

 

 

 

 

[5]         Schedule 3, after entry for Lenograstim

              insert in the columns in the order indicated:

 

Levodopa with

Carbidopa

C3704

 

Where the patient is receiving treatment at/from a public hospital

 

Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy.

 

Treatment must be commenced in a hospital-based movement disorder clinic

Compliance with Written or Telephone Authority Required procedures – Streamlined Authority Code 3704

 

C3705

 

Where the patient is receiving treatment at/from a private hospital

 

Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy.

 

Treatment must be commenced in a hospital-based movement disorder clinic

Compliance with Written or Telephone Authority Required procedures

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.